495 related articles for article (PubMed ID: 29578580)
81. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Svetel M; Tomić A; Kresojević N; Kostić V
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
[TBL] [Abstract][Full Text] [Related]
82. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Singh A; Naidu PS; Kulkarni SK
Pharmacology; 2003 Jun; 68(2):81-8. PubMed ID: 12711835
[TBL] [Abstract][Full Text] [Related]
83. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
[TBL] [Abstract][Full Text] [Related]
84. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
[TBL] [Abstract][Full Text] [Related]
85. The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study.
Ouma S; Fukae J; Fujioka S; Yamamoto S; Hatano T; Yoritaka A; Okuma Y; Kashihara KI; Hattori N; Tsuboi Y
Intern Med; 2017; 56(15):1961-1966. PubMed ID: 28768964
[TBL] [Abstract][Full Text] [Related]
86. The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.
Costa-Mallen P; Checkoway H; Fishel M; Cohen AW; Smith-Weller T; Franklin GM; Swanson PD; Costa LG
Neurosci Lett; 2000 Jan; 278(1-2):33-6. PubMed ID: 10643794
[TBL] [Abstract][Full Text] [Related]
87. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
88. Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
Hattori N; Kabata D; Asada S; Kanda T; Nomura T; Shintani A; Mori A
PLoS One; 2023; 18(12):e0269969. PubMed ID: 38134023
[TBL] [Abstract][Full Text] [Related]
89. When should levodopa therapy be initiated in patients with Parkinson's disease?
Halkias IA; Haq I; Huang Z; Fernandez HH
Drugs Aging; 2007; 24(4):261-73. PubMed ID: 17432922
[TBL] [Abstract][Full Text] [Related]
90. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
[TBL] [Abstract][Full Text] [Related]
91. Association of Catechol-O-Methyltransferase Gene Polymorphisms and Haplotypes in the Levodopa-Induced Adverse Events in Subjects with Parkinson's Disease.
Fatima TS; Fathima ST; Kandadai RM; Borgohain R; Sreenu B; Kutala VK
Indian J Clin Biochem; 2023 Apr; 38(2):262-274. PubMed ID: 37025429
[TBL] [Abstract][Full Text] [Related]
92. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
[TBL] [Abstract][Full Text] [Related]
93. Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.
Zhang Y; Feng S; Nie K; Zhao X; Gan R; Wang L; Zhao J; Tang H; Gao L; Zhu R; Wang L; Zhang Y
J Neurol Sci; 2016 Oct; 369():347-353. PubMed ID: 27653922
[TBL] [Abstract][Full Text] [Related]
94. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
[TBL] [Abstract][Full Text] [Related]
95. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
96. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
97. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
Strong JA; Dalvi A; Revilla FJ; Sahay A; Samaha FJ; Welge JA; Gong J; Gartner M; Yue X; Yu L
Mov Disord; 2006 May; 21(5):654-9. PubMed ID: 16435402
[TBL] [Abstract][Full Text] [Related]
98. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.
Klebe S; Golmard JL; Nalls MA; Saad M; Singleton AB; Bras JM; Hardy J; Simon-Sanchez J; Heutink P; Kuhlenbäumer G; Charfi R; Klein C; Hagenah J; Gasser T; Wurster I; Lesage S; Lorenz D; Deuschl G; Durif F; Pollak P; Damier P; Tison F; Durr A; Amouyel P; Lambert JC; Tzourio C; Maubaret C; Charbonnier-Beaupel F; Tahiri K; Vidailhet M; Martinez M; Brice A; Corvol JC; ;
J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):666-73. PubMed ID: 23408064
[TBL] [Abstract][Full Text] [Related]
99. Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson's disease.
Richmond AM; Lyons KE; Pahwa R
Expert Opin Drug Saf; 2023; 22(7):563-579. PubMed ID: 37401865
[TBL] [Abstract][Full Text] [Related]
100. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
Matsumoto C; Shinkai T; Hori H; Ohmori O; Nakamura J
Psychiatry Res; 2004 Jun; 127(1-2):1-7. PubMed ID: 15261699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
